Back
ghmdsb | 20823

MDS Panel Mutations (blood)

Keywords:
ET
Essential thrombocythaemia
MPN
Myeloproliferative neoplasms NGS
PMF
PV
Polycythaemia vera
primary myelofibrosis

Status

Material
Blood EDTA EDTA tube, purple (6)
Hint

ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. | Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent).

Min. volume 4 mL
Stability
Stability
1 day / 18-25°C; 4 days / 2-8°C
Duration 5 days
Frequency 2 x per week
Method Next Generation Sequencing

Price/Rate

Price
Price
CHF 2’554.90
Rate
Rate
2'554.90 TP